Nicox, Second notice of the Ordinary and Extraordinary Shareholders Meeting on May 6, 2024 and appointment of an ad hoc agent

France - Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, informs its shareholders that the Ordinary and Extraordinary General Meeting, having been unable to deliberate on April 10, 2024 as the quorum required by law has not been reached, will be held, on second convening, on Monday May 6, 2024 at 2:30 p.m., at the offices of BuroClub - Drakkar 2 Btiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis.

The agenda and the draft resolutions for the Ordinary and Extraordinary Shareholders' Meetings remain unchanged and are included in the notice of meeting published in Bulletin des Annonces Legales Obligatoires no.36 of March 22, 2024 (no. 2400592).

About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox generates revenue from VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Conatct:

Gavin Spencer

Tel: +33 (0)4 97 24 53 00

Email: communications@nicox.com

Disclaimer

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox's business are presented in section 2.7 of the 'Rapport Annuel 2022' and in section 4 of the 'Rapport semestriel financier et d'activite 2023' which are available on Nicox's website (www.nicox.com). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.